Zobrazeno 1 - 8
of 8
pro vyhledávání: ''
Publikováno v:
BMJ Case Rep
A male term neonate was admitted to the neonatal intensive care unit in the first hours of life with central cyanosis. Echocardiogram showed severe biventricular hypertrophy, markedly right-sided, tricuspid regurgitation, a patent foramen ovale and a
Publikováno v:
Drug and Therapeutics Bulletin. 59:185-188
The US Food and Drug Administration (FDA) has approved two drugs for ‘hypoactive sexual desire disorder’ in women, flibanserin (Addyi) in 2015 and bremelanotide (Vyleesi) in 2019. In this paper we examine the outcome measures and clinical trial d
Publikováno v:
BMJ Case Rep
In this case study, we explore a case of bilateral acute angle closure (AAC) attack detected in a 52-year-old female patient with no other ophthalmic background or predisposition to angle closure, following an increase of her regular sumatriptan dose
Publikováno v:
Drug and Therapeutics Bulletin. 56:136-139
In the prevention and treatment of thromboembolic disease, novel oral anticoagulants have emerged as alternatives to warfarin. A major challenge continues to be the reversal of their anticoagulant effect in the case of life-threatening haemorrhagic c
Publikováno v:
Drug and Therapeutics Bulletin. 56:107-111
Key learning points Labetalol is a racemate with alpha and non-selective beta adrenoceptor antagonist activity.1 The National Institute for Health and Care Excellence (NICE) recommends labetalol as first-line antihypertensive treatment for non-severe
Publikováno v:
Drug and Therapeutics Bulletin. 59:146-146
Until now, progestogen-only contraceptive pills (POPs) have been available as prescription-only medicines (POMs). Following a consultation process earlier in the year, the Medicines and Healthcare products Regulatory Agency (MHRA) announced that two
Autor:
Joanna Girling
Publikováno v:
Drug and Therapeutics Bulletin. 58:98-98
Pregnant women should be booked by their midwife by 10 weeks and 6 days’ gestation to optimise informed decision-making about early pregnancy care such as antenatal screening tests and the need to start low-dose aspirin for those at high risk of pr
Autor:
Zhu X, Newton S, Xue M, Pullum T, Hodgins S, Afari-Asiedu S, Johary J, Mullany Lc, Orozco-Diaz Jg, Goldthwaite Lm, Kuhn Wc, Morrow M, Sabbe Pj, Tasci Y, Jens Müller, Agyemang Ct, Flexer, Langston A, Heiko Rühl, Johannes Oldenburg, Xu D, Bernd Pötzsch, Velu Pp, Thompson P, Weiss J, Wildemeersch D, Karcaaltincaba D, Teal Sb, L. Schröder, Rudlowski C, Erkaya S, Seckin L, J Welz, Holguin-Hernandez E, Landegger J, S Sukhitashvili, Polat Og, Adiibokah E, Dowsett Mg, Ozdogan S
Publikováno v:
Drug and Therapeutics Bulletin. 52:90-93
▼Zoely is the second estradiol-containing oral contraceptive formulated as an 'extended regimen' (pill-free interval7 days) to be licensed in the UK. However, unlike the quadraphasic estradiol-containing contraceptive Qlaira, it is a monophasic pre